Veracyte Secures Medicare Coverage for Prosigna Test
MolDX Medicare coverage for Veracyte’s Prosigna Breast Risk of Recurrence test takes effect Aug. 19, 2026, for eligible postmenopausal patients with ER-positive early-stage disease.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.